Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entryWESTBY, Mike; SMITH-BURCHNELL, Caroline; MORI, Julie et al.Journal of virology. 2007, Vol 81, Num 5, pp 2359-2371, issn 0022-538X, 13 p.Article

Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1CORBAU, Romuald; MORI, Julie; KNÖCHEL, Thorsten et al.Antimicrobial agents and chemotherapy. 2010, Vol 54, Num 10, pp 4451-4463, issn 0066-4804, 13 p.Article

Pyrazole NNRTIs 3: Optimisation of physicochemical propertiesMOWBRAY, Charles E; CORBAU, Romuald; HAWES, Michael et al.Bioorganic & medicinal chemistry letters (Print). 2009, Vol 19, Num 19, pp 5603-5606, issn 0960-894X, 4 p.Article

Overcoming HERG affinity in the discovery of the CCR5 antagonist maravirocPRICE, David A; ARMOUR, Duncan; DE GROOT, Marcel et al.Bioorganic & medicinal chemistry letters (Print). 2006, Vol 16, Num 17, pp 4633-4637, issn 0960-894X, 5 p.Article

Baseline CD4⁺ T―cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment―experienced patientsSCHAPIRO, Jonathan M; BOUCHER, Charles Ab; PERROS, Manos et al.Antiviral therapy (London). 2011, Vol 16, Num 3, pp 395-404, issn 1359-6535, 10 p.Article

Novel Indazole Non-Nucleoside Reverse Transcriptase Inhibitors Using Molecular Hybridization Based on Crystallographic OverlaysJONES, Lyn H; ALLAN, Gill; PERROS, Manos et al.Journal of medicinal chemistry (Print). 2009, Vol 52, Num 4, pp 1219-1223, issn 0022-2623, 5 p.Article

Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-Using virus reservoirWESTBY, Mike; LEWIS, Marilyn; WHITCOMB, Jeannette et al.Journal of virology. 2006, Vol 80, Num 10, pp 4909-4920, issn 0022-538X, 12 p.Article

New Small-Molecule Inhibitor Class Targeting Human Immunodeficiency Virus Type 1 Virion MaturationBLAIR, Wade S; CAO, Joan; PICKFORD, Chris et al.Antimicrobial agents and chemotherapy. 2009, Vol 53, Num 12, pp 5080-5087, issn 0066-4804, 8 p.Article

An inhibitor of the epidermal growth factor receptor function does not affect the ability of human papillomavirus 11 to form warts in the xenografted immunodeficient mouse modelPARKINSON, Tanya; HOWETT, Mary K; WELSH, Patricia A et al.Antiviral research. 2007, Vol 74, Num 1, pp 43-50, issn 0166-3542, 8 p.Article

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activityDORR, Patrick; WESTBY, Mike; WEBSTER, Rob et al.Antimicrobial agents and chemotherapy. 2005, Vol 49, Num 11, pp 4721-4732, issn 0066-4804, 12 p.Article

Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5 : Effects of viral diversity, target cell and receptor densityWILLEY, Samantha; PETERS, Paul J; SULLIVAN, W. Matthew et al.Antiviral research. 2005, Vol 68, Num 2, pp 96-108, issn 0166-3542, 13 p.Article

Disease-Modifying Therapeutic Concepts for HIV in the Era of Highly Active Antiretroviral TherapyBUTLER, Scott L; VALDEZ, Hernan; TEBAS, Pablo et al.Journal of acquired immune deficiency syndromes (1999). 2011, Vol 58, Num 3, pp 297-303, issn 1525-4135, 7 p.Article

Design and optimisation of potent gp120-CD4 inhibitorsTRAN, Thien-Duc; ADAM, Fiona M; PARKINSON, Tanya et al.Bioorganic & medicinal chemistry letters (Print). 2009, Vol 19, Num 17, pp 5250-5255, issn 0960-894X, 6 p.Article

Discovery of a small molecule inhibitor through interference with the gp120-CD4 interactionWILLIAMS, David H; ADAM, Fiona; PERROS, Manos et al.Bioorganic & medicinal chemistry letters (Print). 2009, Vol 19, Num 17, pp 5246-5249, issn 0960-894X, 4 p.Article

Pyrazole NNRTIs 1: Design and initial optimisation of a novel templateMOWBRAY, Charles E; BURT, Catherine; CORBAU, Romuald et al.Bioorganic & medicinal chemistry letters (Print). 2009, Vol 19, Num 19, pp 5599-5602, issn 0960-894X, 4 p.Article

Pyrazole NNRTIs 4: Selection of UK-453,061 (lersivirine) as a Development CandidateMOWBRAY, Charles E; BURT, Catherine; STUPPLE, Paul A et al.Bioorganic & medicinal chemistry letters (Print). 2009, Vol 19, Num 20, pp 5857-5860, issn 0960-894X, 4 p.Article